Oct 26 (Reuters) - Resverlogix Corp RVX.TO :
* A SECOND PUBLICATION SHORTLISTS RESVERLOGIX CLINICAL CANDIDATE APABETALONE FOR ITS POTENTIAL COVID-19 EFFECTIVENESS INCLUDING REDUCING CYTOKINE STORMS
Oct 26 (Reuters) - Resverlogix Corp RVX.TO :
* A SECOND PUBLICATION SHORTLISTS RESVERLOGIX CLINICAL CANDIDATE APABETALONE FOR ITS POTENTIAL COVID-19 EFFECTIVENESS INCLUDING REDUCING CYTOKINE STORMS